Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
34.63
-0.79 (-2.23%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 27, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
November 21, 2024
Via
Benzinga
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
November 19, 2024
Via
Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
November 12, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
November 04, 2024
Via
Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
November 04, 2024
Via
Benzinga
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
October 16, 2024
Via
Benzinga
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
September 13, 2024
Via
Benzinga
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
November 06, 2024
Via
Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
November 05, 2024
Sales of the company's top commercialized product didn't meet expectations.
Via
The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
November 05, 2024
The company is best known for its drug, Syfovre, a treatment for geographic atrophy.
Via
Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 05, 2024
Via
Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 05, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
October 29, 2024
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
Via
The Motley Fool
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
October 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
October 22, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...
Via
Benzinga
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
October 16, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 25, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
September 23, 2024
Via
Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
September 20, 2024
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following...
Via
Benzinga
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
September 20, 2024
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst.
Via
Investor's Business Daily
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
September 20, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 29, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
August 13, 2024
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some.
Via
InvestorPlace
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary...
Via
Benzinga
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 08, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.